BR0213899A - Aminopirimidinas e aminopiridinas - Google Patents

Aminopirimidinas e aminopiridinas

Info

Publication number
BR0213899A
BR0213899A BR0213899-9A BR0213899A BR0213899A BR 0213899 A BR0213899 A BR 0213899A BR 0213899 A BR0213899 A BR 0213899A BR 0213899 A BR0213899 A BR 0213899A
Authority
BR
Brazil
Prior art keywords
aminopyrimidines
aminopyridines
aminopyrimidine
metabolic
inflammatory
Prior art date
Application number
BR0213899-9A
Other languages
English (en)
Inventor
Ronald Charles Hawley
Sharada Shenvi Labadie
Eric Brian Sjogren
Francisco Xavier Talamas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0213899A publication Critical patent/BR0213899A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"AMINOPIRIMIDINAS E AMINOPIRIDINAS". A presente invenção inveção refere-se a derivados de aminopirimidina e aminopiridina tendo a fórmula (I), em que V, X, Y, Z, R^ 1^, R^ 4^, A, B e U possuem o valor dado no relatório descritivo. Os compostos são úteis como um inibidor de IkB cinases e, portanto, podem ser usados para o tratamento de condições inflamatórias, metabólicas ou malignas.
BR0213899-9A 2001-11-07 2002-10-31 Aminopirimidinas e aminopiridinas BR0213899A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33831201P 2001-11-07 2001-11-07
PCT/EP2002/012164 WO2003040131A1 (en) 2001-11-07 2002-10-31 Aminopyrimidines and pyridines

Publications (1)

Publication Number Publication Date
BR0213899A true BR0213899A (pt) 2004-08-31

Family

ID=23324288

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213899-9A BR0213899A (pt) 2001-11-07 2002-10-31 Aminopirimidinas e aminopiridinas

Country Status (12)

Country Link
US (2) US6846828B2 (pt)
EP (1) EP1444223A1 (pt)
JP (1) JP2005511608A (pt)
KR (1) KR20050042062A (pt)
CN (1) CN1582284A (pt)
AR (1) AR039554A1 (pt)
BR (1) BR0213899A (pt)
CA (1) CA2465711A1 (pt)
MX (1) MXPA04004166A (pt)
PL (1) PL370480A1 (pt)
RU (1) RU2308455C2 (pt)
WO (1) WO2003040131A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7442697B2 (en) * 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205690D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
CN100441569C (zh) * 2003-02-24 2008-12-10 横滨橡胶株式会社 化合物和使用了该化合物的组合物
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP3962425B2 (ja) * 2003-10-14 2007-08-22 ファルマシア・コーポレーション 炎症治療用置換ピラジノン化合物
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
PL1809624T3 (pl) * 2004-08-28 2014-03-31 Astrazeneca Ab Pochodne pirymidynosulfonoamidu jako modulatory receptora chemokinowego
WO2006064251A1 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
GB0514017D0 (en) * 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
MX2008001428A (es) * 2005-07-30 2008-04-04 Astrazeneca Ab Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
WO2007036732A1 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
AR058277A1 (es) * 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008127302A2 (en) * 2006-10-27 2008-10-23 Genyous BioMed International, Inc. Compositions for treatment and inhibition of pain
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11427556B2 (en) 2017-11-17 2022-08-30 Hepagene Therapeutics (HK) Limited Urea derivatives as inhibitors of ASK1
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
KR102441327B1 (ko) * 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
CN109336800B (zh) * 2018-09-17 2022-11-29 江西中医药大学 一种dhnb缩苯基氨基硫脲化合物及其制备方法和用途
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095240A (en) * 1981-03-05 1982-09-29 Fujisawa Pharmaceutical Co Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
EP0457717B1 (de) 1990-05-16 1995-10-25 Sulzer Chemtech AG Verfahren zur gerichteten fraktionierten Kristallisation
EP0457727A1 (de) * 1990-05-17 1991-11-21 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
IL106786A (en) * 1992-09-10 1997-02-18 Basf Ag Substituted pyridine derivatives and fungicidal compositions containing them
ATE308982T1 (de) * 2000-02-02 2005-11-15 Dorian Bevec Aromatisches guanylhydrazon zur behandlung resistenter viraler infektionen
KR20030064773A (ko) * 2000-10-26 2003-08-02 툴라릭, 인코포레이티드 항염증제

Also Published As

Publication number Publication date
AR039554A1 (es) 2005-02-23
US20030144303A1 (en) 2003-07-31
MXPA04004166A (es) 2004-07-08
PL370480A1 (en) 2005-05-30
KR20050042062A (ko) 2005-05-04
US20050107403A1 (en) 2005-05-19
US7157580B2 (en) 2007-01-02
JP2005511608A (ja) 2005-04-28
RU2308455C2 (ru) 2007-10-20
RU2004117545A (ru) 2005-05-27
CA2465711A1 (en) 2003-05-15
US6846828B2 (en) 2005-01-25
EP1444223A1 (en) 2004-08-11
CN1582284A (zh) 2005-02-16
WO2003040131A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
BR0213899A (pt) Aminopirimidinas e aminopiridinas
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE270278T1 (de) Phthalazinone pde iii/iv hemmer
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
RS20050201A (en) Heterocyclic compounds
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DK1686119T3 (da) Pyrimidin-5-on-derivater som LDL-PLA2 inhibitorer
DK1474395T3 (da) Nicotinamidderivater, der er nyttige som p38-inhibitorer
MXPA02005844A (es) Inhibidores de cinasas de proteina.
BRPI0414480A (pt) derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
HRP20090078A2 (en) Novel pyridazine compound and use thereof
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
BRPI0407841A (pt) inibidores heterocìclicos de quinase
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
TR200302077T4 (tr) 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit
ES2180449A1 (es) Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
MA27077A1 (fr) Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
ATE374189T1 (de) Phthalazinon-derivate als pde 4 hemmer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.